152873-78-4

Basic information

• Product Name: 1,4-Naphthalenebis(trifluoroMethanesulfonate)
• Synonyms: 1,4-Naphthalenebis(trifluoroMethanesulfonate)
• CAS NO: 152873-78-4
• Molecular Formula: C₁₂H₆F₆O₆S₂
• Molecular Weight: 426.3087392
• Mol File: 152873-78-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 35.5-37 °C
• Boiling Point: 443.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.721±0.06 g/cm3(Predicted)
• Solubility: soluble in Toluene
• CAS DataBase Reference: 1,4-Naphthalenebis(trifluoroMethanesulfonate)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Naphthalenebis(trifluoroMethanesulfonate)(152873-78-4)
• EPA Substance Registry System: 1,4-Naphthalenebis(trifluoroMethanesulfonate)(152873-78-4)

Safety Data

• Hazardous Substances Data: 152873-78-4(Hazardous Substances Data)

Usage

Physical state

Colorless liquid

Use

Coupling agent in organic synthesis

Specific role

Sulfonate ester transfer reagent

Reactivity

High

Function

Efficiently transfers the triflate group to various nucleophiles

Importance

Valuable tool in synthetic chemistry

Applications

Preparation of complex organic molecules in academic and industrial research settings

Safety

Toxic and can cause skin and eye irritation upon contact

Handling

Should be handled with caution

Upstream product

• 108-75-8 2,4,6-trimethyl-pyridine 
• 130-15-4 [1,4]naphthoquinone 
• 571-60-8 1,4-Dihydroxynaphthalene 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 2243-61-0 1,4-diaminonaphthalene 
• 1207336-74-0 C₃₆H₂₄ 

Relevant articles and documents

Direct Synthesis of Hydroquinones from Quinones through Sequential and Continuous-Flow Hydrogenation-Derivatization Using Heterogeneous Au–Pt Nanoparticles as Catalysts

Pt–Au bimetallic nanoparticle catalysts immobilized on dimethyl polysilane (Pt–Au/(DMPSi-Al2O3)) have been developed for selective hydrogenation of quinones to hydroquinones. High reactivity, selectivity, and robustness of the catalysts were confirmed under continuous-flow conditions. Various direct derivatizations of quinones, such as methylation, acetylation, trifluoromethanesulfonylation, methacrylation, and benzoylation were successfully performed under sequential and continuous-flow conditions to afford the desired products in good to excellent yields. Especially, air-sensitive hydroquinones, such as anthrahydroquinones and naphthohydroquinones, could be successfully generated and derivatized under closed sequential and continuous-flow conditions without decomposition.

ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME

PROBLEM TO BE SOLVED: To provide an anthracene derivative desirably having controlled solubility, deposition property, wet coating property and orientation property (further desirably thermal stability) and an electroluminescent element excellent in at least one of efficacy, life and driving voltage by using the compound as a constituent of the electroluminescent element. SOLUTION: There is provided an anthracene derivative represented by the following formula (1). Ar-An-L-FG (1), where An is anthracene, Ar is aryl having 6 to 18 carbon atoms which may be substituted, L is arylene having 7 to 18 carbon atoms which may be substituted and 2 or more rings are condensed and FG is an oligophenylene structure bound at a meta position which may be substituted (functional group). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Novel seco cyclopropa[c]pyrrolo[3,2-e]indole bisalkylators bearing a 3,3′-arylenebisacryloyl group as a linker

We synthesized the novel seco cyclopropa[c]pyrrolo[3,2-e]indole (CPI) bisalkylators and evaluated their antitumor activity. Among these derivatives, 11a (AT-760), in which the two seco 3-methoxycarbonyl-2-trifluoromethyl CPI (MCTFCPI) moieties are connected with a 3,3′-(1,4-phenylene)bisacryloyl group, was found to exhibit more potent cytotoxicity and antitumor activity against HeLaS3 human uterine cervix carcinoma cells and Colon 26 adenocarcinoma cells, respectively, than 8 (bizelesin, U-77,779). It also appeared that compound 11a exhibits improved in vivo efficacy in the human colon CX-1 model when compared to either compound 8 or mitomycin C (MMC). Efficacious doses for 11a were found to be 2-fold lower than those for 8.